U.S. Semiconductors Stock News

If you have been watching GoodRx Holdings lately, you are probably weighing whether its current price reflects a hidden bargain or just more risk. At $4.39, the stock has certainly traveled a bumpy road. Despite a nice pop of nearly 4% over the last week, and almost 10% across the past month, the longer-term chart remains tough to ignore. Down roughly 37% over the last year and an eye-catching 92% since its five-year high, GoodRx has given investors moments of excitement mixed with plenty of...

Battery storage is no longer a niche corner of clean tech.  It’s emerging as the backbone of America’s energy future.

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

B.O.S. Better Online Solutions Ltd. ( NASDAQ:BOSC ) just reported healthy earnings but the stock price didn't move...

If you're considering what to do with your Healthcare Realty Trust shares, or perhaps thinking about making a move, you're not alone. The stock has been making waves, sometimes subtle, sometimes more noticeable. Over just the past week, there was a minimal dip of -0.1%, and the past month has seen a slightly larger decline of -1.8%. Yet, zooming out, things look far sunnier: Healthcare Realty Trust is up 7.7% so far this year and a solid 9.5% over the last twelve months. Of course, anyone who...

If you’ve been tracking SiriusPoint’s stock, you know this isn’t one of those sleepwalking tickers. Whether you’re eyeing that impressive 259.4% gain over the last three years or sizing up this year’s 15.8% return, SiriusPoint has certainly kept things interesting for shareholders. Even with a slight dip over the last month, it’s clear that investors are reassessing the company’s growth prospects and its risk, potentially setting up for the next big move. Much of the recent momentum seems...

Art's-Way Manufacturing's (NASDAQ:ARTW) stock is up by a considerable 22% over the past three months. Since the market...

If you have been watching Wolfspeed stock recently, you have likely noticed some eye-catching movement. After a period of relative calm, shares have surged by 18.4% in the last week alone. For anyone weighing an investment decision, that kind of action can signal renewed optimism in the company or a shift in how the market is assessing risk and reward in this situation. So what is driving all this buzz? Part of it may be broader developments in the semiconductor industry, where Wolfspeed is a...

Skye Bioscience (SKYE) has scheduled a special call to present topline data from its Phase 2a clinical trial of Nimacimab, focusing on both monotherapy and combination treatment. Updates like these frequently shape investor sentiment around development-stage biotech stocks. See our latest analysis for Skye Bioscience. Skye Bioscience’s latest topline clinical update arrives after a period of muted share price action. Its stock closed at $1.90 and has shown minimal momentum over recent months...

If you are looking for the next move on Soho House & Co stock, you have probably noticed its eye-catching trajectory. This is not a slow and steady story, but one with dramatic swings and the kind of big numbers that spark conversation. Just over the past year, Soho House & Co’s shares have surged 69.1%. If you stretch that lens out to three years, we are talking 114.5% growth, which is well beyond what most lifestyle or hospitality names can boast. Even in recent months, the stock has kept...

If you have been watching Rush Enterprises, you may be asking yourself whether now is the moment to buy, hold, or move on. The stock price has slipped by 7.3% in the past week and it is down more than 14% over the last month. Year to date, shares have shed 8.8%. On a longer horizon, however, Rush Enterprises has quietly put together an impressive run, climbing 70.8% over three years and more than doubling investors’ money over five years with a 114.6% gain. That kind of return turns heads,...

The Morning Bull - US Market Morning Update Tuesday, Oct, 7 2025 US stock futures are moving lower ahead of the open as persistent political uncertainty in both the US and Europe weighs on sentiment. With the US government shutdown showing no signs of resolution and French bond yields near multi-year highs because of fiscal and leadership gridlock, investors are focused on how these tensions could drive volatility and put pressure on areas of the market most sensitive to economic momentum and...

RBC Capital has reiterated its positive outlook for Brookfield Renewable, highlighting enhanced growth visibility and strong confidence in the company's long-term expansion plans following recent operational results. Despite reporting lower-than-expected Q2 2025 profits, Brookfield Renewable saw a 10% year-over-year rise in Funds From Operations, driven largely by its hydropower and distributed energy businesses. We'll examine how analyst confidence in Brookfield Renewable's operational...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...

Eagle Materials' (NYSE:EXP) stock up by 9.7% over the past three months. Given that the market rewards strong...

If you are considering what to do with Essex Property Trust stock right now, you are not alone. Many investors are weighing whether the recent dip is a sign of opportunity or cause for caution. After a three-year return of 32.5% and a five-year gain of 43.5%, Essex has clearly delivered for long-term investors. Lately, though, the story has been a little bumpier. The stock closed recently at $261.34, down 1.8% in the last week, 2.5% for the past month, and 6.5% year to date. Even over the...

On October 6, 2025, Senseonics Holdings announced preliminary unaudited revenue for the third quarter ended September 30, reporting approximately US$8.1 million, an increase of 91% over the same period in 2024, primarily attributed to roughly 160% new patient growth in the U.S. This upturn in both revenue and new patient adoption highlights more robust market traction, suggesting a potential acceleration in demand for the company’s continuous glucose monitoring systems. We’ll now explore how...

If you're standing at the crossroads of what to do with your Knife River shares or thinking of putting some capital to work, you're not alone. Knife River’s recent performance has grabbed the attention of both cautious investors and opportunists, sparking plenty of debate on whether the current price fairly reflects the company’s long-term prospects. Knife River's stock price has seen a difficult stretch lately. Down 3.9% in the last week, 11.6% in the last month, and a hefty 29.2%...

AC Immune (NasdaqGM:ACIU) just shared peer-reviewed data from its Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau in early Alzheimer's, developed with Janssen. The findings highlight a rapid and sustained antibody response as well as a clean safety profile. See our latest analysis for AC Immune. With this encouraging clinical update, AC Immune is starting to turn heads, especially as the company’s latest innovation underscores its growing potential in Alzheimer’s...

In September 2025, Bayer’s Consumer Health division announced it had selected Interpublic Group as its exclusive global creative, production, and media agency partner for iconic self-care brands including Aspirin and Claritin. This partnership signals Bayer’s commitment to integrated marketing powered by GenAI for both global consistency and tailored local consumer engagement. We'll review how IPG’s appointment as Bayer’s lead global partner could strengthen its client portfolio and...

Cheche Group Inc.'s ( NASDAQ:CCG ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment...

Verizon Communications Inc. ( NYSE:VZ ) stock is about to trade ex-dividend in two days. The ex-dividend date is one...

As of October 2025, the U.S. stock market is experiencing a notable upswing, with both the Nasdaq and S&P 500 reaching new closing highs despite ongoing government shutdown concerns. This positive momentum in major indices highlights investor optimism, particularly in high-growth sectors like technology, where companies are often characterized by innovative products and robust potential for future expansion.

As the U.S. stock market continues to reach new heights, with the Nasdaq and S&P 500 setting fresh closing records, investors are keenly observing opportunities amidst this bullish trend. In such an environment, identifying stocks priced below their estimated value can be a prudent strategy for those looking to potentially capitalize on market inefficiencies.